RECISTv1.1 progression in oncology: Shades of gray
Authors:
- 11 May 2023
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 41 (6) , 1003-1005
Abstract
No abstract availableKeywords
Funding Information
- Merck
This publication has 9 references indexed in Scilit:
- Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumabAnnals of Oncology, 2021
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaNew England Journal of Medicine, 2021
- Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) BlockadeJournal of Clinical Oncology, 2019
- Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer ImmunotherapyJournal of Clinical Oncology, 2018
- Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysisThe Lancet Oncology, 2018
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsThe Lancet Oncology, 2017
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009